February 2017 Volume 13, Issue 2
Volume 13, Issue 2 | February 2017
February 2017
In this Issue
Discovery
Putting the BiTE on cancer
Amgen and Immatics combine expertise to develop next-generation, T cell-engaging bispecific immunotherapiesAgilent and Transcriptic team up
Aim is to provide a broad, convenient solution for synthetic and discovery biology researchAnother feather for Watson’s hat
IBM teams up with Pfizer to use Watson for cancer drug discoveryA ‘crystal’ clear look at CCR2
Skaggs team offers new structural biology insight into promising inflammation targetGlobal drug discovery technologies trends
The Global Drug Discovery Technologies Market is poised to grow at a compound annual growth rate of around 12.2 percent over the next decadeResearch & Development
A flick of the switch
Newly discovered ‘off-switches’ for CRISPR-Cas9 could mean safer, more specific gene editingMinimizing memory loss
TSRI scientists uncover potential clues regarding Alzheimer’s diseaseExploring immuno-oncology potential
Alliance between Pieris Pharmaceuticals and Servier aimed at bispecific therapeuticsTargeting TIGIT
Compugen discloses its cancer immunotherapy program that seeks to combine TIGIT and CGEN-15029 workSpecial Reports
Special Report on Cell Biology: Cytometry for all
As applications broaden, footprints shrinkFeature
Cancer Research News Focus: A tour of the developing cancer landscape
From reproducibility to genomic data sets to the best countries for research, plus a look at what some specific companies and institutions are doingSociety of Toxicology Show Preview: SOT heads to Baltimore
After eight years, the Society of Toxicology brings its annual meeting back to ‘Charm City’Editor's Focus
Cannabinoid research speeding up its pace
In this month's editorial, I studiously avoided almost all of the easy and very tempting puns related to marijuana because the truth is that cannabis-related research is serious business these days; in fact, it long has been, but now it is getting more respect and attentionCommentary
The irreproducibility of published science
Yes, there are issues and problems around the issue of reproducibility in scientific studies, and they need to be addressed; at the same time, there are reasons this area is challenging, and there is no reason to denigrate science overall because of itGuest Commentary: Validating antibodies-- The good, the bad and the necessary
Although there are no universally accepted guidelines to ensure that antibodies have been properly validated, there are steps that can (and should) be taken by both the antibody industry and the researchers who use antibodies to improve that situationQ&A
Q&A: The importance of oxygen in cell cultures
Panasonic Healthcare’s Carl Radosevich talks oxygenation and cell culturing with DDNewsContract Services
Enamine and Pcovery extend discovery collaboration
A key focus is discovery of new drugs for the treatment of invasive fungal infectionsERT acquires Exco InTouch
Merging of two companies opens up possibilities in the ‘bring your own device’ marketClinTec wins scale-up business award
In addition, company CEO was a finalist for entrepreneur awardDiagnostics
Videssa victory
Provista Diagnostics reveals positive findings for its blood-based breast cancer testLiquid biopsy in the palm of your hand
Two Pore Guys and UCSF collaborate on study with first handheld device for cancer monitoringClinical Genomics launches Colvera
Blood-based test is intended for early detection of colorectal cancerPreclinical
Masitinib on muscles
Compound may protect muscles and nerves in amyotrophic lateral sclerosis sufferersProgress on prostate and breast with AEB3103
Aeglea BioTherapeutics finds product candidate effective in slowing cancer growthSkin in the game
Preclinical data show Novan’s SB414 could be promising for treating psoriasisA Kinoid collaboration
Neovacs, Sunnybrook Research Institute unite for immunotherapy preclinical development and proof of conceptClinical Trials
‘Unusual’ antibody
Bird Rock Bio starts first-in-human clinical trial for namacizumab, enters two collaborationsAddressing lactose intolerance via the microbiome
Ritter Pharmaceuticals publishes Phase 2a lactose intolerance clinical trial dataOptimistic news for FCS and FPL patients
Akcea and Ionis announce auspicious results from COMPASS studyGood news for GEN-003
Six-month results for genital herpes therapy are positive; Genocea on course to begin Phase 3 in Q4Business & Government Policy
Breaking down gluten
Takeda helps PvP tackle celiac diseaseFighting the rise of antimicrobial resistance
U.K.’s Auspherix sets stage for new direction in developing antibacterialsOn the cutting edge
A roundup of instrumentation, software and other tools and technology news
